Royalty Report: Drugs, Gastrointestinal, Pain – Collection: 280946

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Gastrointestinal
  • Pain
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Personal Care
  • Healthcare

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 280946

License Grant
Licensor agrees to grant and hereby grants to Licensee the following licenses, with the right to sublicense, under the Licensor Patents and Licensor Know-How (i) an exclusive (even as to Licensor) license in the Territory to develop, import, use, sell and offer for sale Licensed Products for Licensed Indications in the Field; and (ii) a non-exclusive worldwide license to develop, import, make and have made Licensed Products solely for sale in the Territory in the Field, which license shall be exclusive, even as to Licensor, regarding import and sale of Licensed Products in the Field in the Territory.
License Property
Licensor Patents means (i) the patents and patent applications listed, including those in-licensed by Licensor in the Missouri Agreement; and (ii) all additional patent applications and patents owned or Controlled by Licensor in the Territory which are directed to pharmaceutical products containing one or more PPIs with one or more buffering agents and which pharmaceutical products provide for immediate release of the PPI included in such product.
5,840,737 – Omeprazole solution and method for using same
6,489,346 – Substituted benzimidazole dosage forms and method of using same
6,780,882 – Substituted benzimidazole dosage forms and method of using same

Product(s) means pharmaceutical compositions containing any one or more PPIs in combination with one or more buffering agents, which pharmaceutical compositions provide for immediate release of the PPI included in such product, including (i) any prodrugs and metabolites, and all esters, salts, hydrates, solvates, polymorphs and isomers of any of the above, (ii) chemical analogs, and (iii) Formulations (including tablets, chewable tablets, capsules, caplets, liquid forms and powders for oral suspensions) of any of the above.

PPI means proton pump inhibitor.

Licensed Product(s) means any of the following OTC Products (i) Products containing a 20 mg dose of omeprazole and no other PPI, (ii) Products containing omeprazole (and no other PPI) at doses other than 20 mg, (iii) Combination Products that are approved.

OTC Product means all Formulations, dosages, package sizes and configurations and types of Products for which a prescription from a health care practitioner is not required in order to dispense, purchase or use such Product in the Territory.

The product is Zegerid® branded immediate-release omeprazole products for the over-the-counter (“OTC”).  Zegerid is a proton pump inhibitor (PPI), the strongest and most effective class of acid-reducing medication for treating frequent heartburn.

Field of Use
Field means all therapeutic uses and Indications in humans for which a physician’s prescription is not required. This may be used interchangeably with the phrase “OTC market”.
It can treat heartburn, a damaged esophagus, stomach ulcers, and gastroesophageal reflux disease (GERD).

IPSCIO Record ID: 299275

License Grant
Licensor hereby grants to Netherlands Licensee and its Affiliates
(a) an exclusive license under the Other Licensor IP to sell, offer for sale, have sold, import and have imported for sale Licensed Products in the Field in the Territory. Additionally, subject to the terms and conditions of this Agreement (including without limitation Section 2.1.2), Licensor hereby grants to Licensee and its Affiliates a non-exclusive license under (i) the Other Licensor IP to develop and use Licensed Products in the Field in the Territory; and (ii) (a) the Other Licensor IP and (b) the Know-How and Patents outside the Territory which are Controlled by Licensor and which are reasonably necessary to make Licensed Products, in each case to make and have made Licensed Products anywhere in the world solely for the purpose of supplying Licensed Products for Licensee’s and its Affiliates’ exercise of the license granted in this Agreement (or any Sublicensee’s exercise of a sublicense granted; and
          (b) an exclusive sublicense under the University IP to sell, offer for sale, have sold, import and have imported for sale Licensed Products in the Field in the Territory.
License Property
Licensed Product(s) means (a) the following immediate-release pharmaceutical products incorporating omeprazole in combination with one or more buffering agents, for which regulatory approval has been obtained by Licensor in the Field from the FDA as of the Effective Date Zegerid® (omeprazole/sodium bicarbonate) Capsules, Zegerid® (omeprazole/sodium bicarbonate) Powder for Oral Suspension, and Zegerid® (omeprazole/sodium bicarbonate/magnesium hydroxide) with Magnesium Hydroxide Chewable Tablets, each in 20 mg and 40 mg dosage strengths of omeprazole; (b) other formulations of immediate-release pharmaceutical products incorporating omeprazole in combination with one or more buffering agents in the Field developed by Licensee following the Effective Date pursuant to this Agreement; and (c) other formulations of immediate-release pharmaceutical products incorporating omeprazole in combination with one or more buffering agents in the Field developed by Licensee following the Effective Date other than pursuant to this Agreement. Notwithstanding the foregoing, in no event shall the definition of Licensed Products or Licensees rights under this Agreement, include products that contain a PPI other than omeprazole.  PPI means any proton pump inhibitor, including those specified from time to time in the Anatomical Therapeutic Chemical (ATC) classification class A02BC.

Other Licensor IP means, individually and collectively, the Other Licensor Patents, and the Licensor Know-How. For clarity, Other Licensor IP includes Licensor Inventions and Licensor’s interest in Joint Inventions (each as defined in this Agreement).

Patent means any of the following, whether existing now or in the future anywhere in the world (a) any issued patent, including any inventor’s certificate, substitution, extension, supplemental protection certificate, registration, confirmation, reissue, re-examination, renewal or any like governmental grant for protection of inventions; and (b) any pending application for any of the foregoing, including any continuation, divisional, substitution, continuations-in-part, provisional and converted provisional applications.

University IP means, individually and collectively, the University Patents and the University Know-How.

University Patents means the Patents listed, together with any and all other Patents in the Territory that are Controlled by University or co-owned by University with Licensor and are licensed to Licensor pursuant to the University Agreement and that claim (specifically or generically) subject matter developed before or after the Effective Date which would be infringed by (a) a formulation of any Licensed Product, (b) a method or process for the manufacture of any Licensed Product, or (c) a method of use or administration of any Licensed Product.
These patents are listed at The European Patent Office (EPO)

Field of Use
Zegerid ® (omeprazole/sodium bicarbonate) Capsules is for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (“GERD”), treatment and maintenance of healing of erosive esophagitis and treatment of duodenal and gastric ulcers.

Field means all therapeutic uses and indications in humans for which a physician’s prescription is required or which require a pharmacist’s approval to purchase. For purposes of clarity, the “Field” is intended to be limited to to products classified as either (i) prescription only medicines or POM or (II) as available in a pharmacy without a prescription buy only under the supervision of a pharmacist or 'P', and is not intended to include products promoted to consumers and classified as general sale list or 'GSL' (or other similar non-prescription and non-pharmacist supervised classification).

IPSCIO Record ID: 204358

License Grant
The parties desire to work together to promote the Products in the United States.  Pursuant to this agreement, where both parties have granted each other trademark use rights,  the Co-promotor Partner/ Licensor shall use its Commercially Reasonable Efforts to market and promote the Products to Co-Promotion Target Healthcare Professionals in the Territory in accordance with the then-current Marketing Plans.  The Co-Promotion Partner has expertise in the promotion of pharmaceutical products.
License Property
Product(s) means the following pharmaceutical prescription products as currently being developed, each having omeprazole as its primary active ingredient, and including all current and future dosage strengths and indications Zegerid(TM) Powder for Oral Suspension, Zegerid(TM) Capsules, or Zegerid(TM) Chewable Tablets.

ZEGERID Powder for Oral Suspension is a proprietary immediate-release formulation of the PPI omeprazole. PPIs are the most frequently prescribed drugs for the treatment of many upper gastrointestinal, or GI, diseases and disorders and enjoy widespread use due to their potent acid suppression, favorable safety profile and once-a-day dosing.

ZEGERID Capsules are indicated for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD), the short-term treatment (four to eight weeks) of erosive esophagitis diagnosed by endoscopy and active benign gastric ulcers, the short-term treatment of active duodenal ulcers and for maintenance of healing of erosive esophagitis (controlled studies do not extend beyond 12 months).

Field of Use
Target Healthcare Professionals means Licensor Target Healthcare Professionals or Licensee Target Healthcare Professionals.

Licensee has exclusive rights to market and distribute the Products in the United States.

IPSCIO Record ID: 260459

License Grant
Licensor grants to the Licensee of Sweden an exclusive license, with the right to grant sublicenses, under the Licensed Technology to make, use, have made, sell, offer for sale, import, and export Products in the Field of Use in the Territory.

Licensor grants a license to use the Licensor House Marks in connection with the Commercialization of Licensor Products in the Field of Use in the Territory.

Licensor grants an option for a period of twenty-four months the Japan Option Period after the Effective Date to include Japan in the Territory to Licensee.

License Property
Licensors Product means any product that combines a Gastroprotective Agent and any NSAID in a single fixed combination dosage form, that would, if made, used, sold, offered for sale, had made, imported or exported without a license from Licensor of the Licensed Patents, infringe one or more Valid Claims of the Licensed Patents.

Esomeprazole means that certain pharmaceutical compound with the name (5-methoxy-2-{(S)-[ ( 4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl }-1 H-benzimidazole ), including any salts, hydrates, solvates, polymorphs and tautomers thereof.

Naproxen means that certain pharmaceutical compound with the chemical name (S)-6-methoxy-(alpha)-methyl-2-naphthaleneaceti,c acid, including any esters, salts, hydrates, solvates and polymorphs thereof.

The patent is for Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs.

Field of Use
Field of Use means the treatment of human diseases and conditions by means of a pharmaceutical product.  These Pharmaceutical Compositions are for the Coordinated Delivery of NSAIDs.

IP relates to the sublicenses’s proprietary fixed dose combinations of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen, in a single tablet.  Naproxen is used to relieve pain from various conditions such as headache, muscle aches, tendonitis, dental pain, and menstrual cramps. It also reduces pain, swelling, and joint stiffness caused by arthritis, bursitis, and gout attacks. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID).

IPSCIO Record ID: 319206

License Grant
Licensee of Curacao exercised its option under the Strategic Alliance Agreement to add the Optional Products Omeprazole DR, 10, 20 and 40 mg to the Agreement as Tier 1 Products. The Omeprazole 40 mg is specifically excluded from this letter agreement.
License Property
Omeprazole Delayed Release Capsules are a generic version of Prilosec(R) marketed by AstraZeneca for the treatment of duodenal/gastric ulcers and GERD (gastro-esophageal reflux disease).
Field of Use
Licensee markets products through three different channels, including Sale of prescription (Rx) products, such as Bupropion Hydrochloride and Omeprazole, exclusively, through marketing partners, pursuant to strategic alliance agreements, called Rx Partners.

IPSCIO Record ID: 234782

License Grant
Per the AcipHex Agreement, the Company is granted the exclusive license to exploit the products in the territory (U.S.) and an exclusive license to use Licensors trademarks to sell the products.  Licensor will manufacture and supply the requirements for supply of the products.
License Property
Trademark = AcipHex

The product, AcipHex, is a prescription drug that treat a range of pediatric diseases, disorders and conditions.  AcipHex is a proton pump inhibitor that decreases the amount of acid produced in the stomach.  It is used for the short-term treatment of symptoms related to gastroesophageal reflux disease and to treat conditions involving excessive stomach acid.

Field of Use
Aciphex Sprinkle is indicated for treatment of Gastroesophageal Reflux Disease (GERD) in pediatric patients.

IPSCIO Record ID: 7537

License Grant
The Licensor grants to the Licensee an exclusive license under the Licensor IP to sell, offer for sale and import for sale Licensed Products for applications in the Field in the Licensee Territory. The Licensor also grants to the Licensee a non-exclusive license under the Licensor IP to develop and use Licensed Products for applications in the Field in the GSK Territory; and to make and have made Licensed Products anywhere in the world to support the other licenses granted. Notwithstanding anything herein to the contrary, the licenses granted shall be limited to formulations of Licensed Products which are capsules, powder for oral suspension or chewable tablets for Approved Indications and other formulations or indications for which the Licensee develops a Licensed Product. The licenses include the right for the Licensee to grant sublicenses.
License Property
The Licensor has developed, manufactures, and is commercializing, in the United States a line of pharmaceutical products based on proton pump inhibitors in combination with one or more buffering agents under the trademark Zegerid®. The Licensed Product means any pharmaceutical product incorporating omeprazole in combination with one or more buffering agents.

Zegerid is a brand name medication included in a group of medications for peptic ulcer and gastro oesophageal reflux disease GORD.

Field of Use
Field means all approved and future human therapeutic indications, for either prescription or over-the-counter distribution.

IPSCIO Record ID: 369293

License Grant
Licensor hereby grants to Licensee an exclusive (even as against Licensor and its Affiliates), nontransferable (except with respect to the assignment provision in Agreement) limited license during the Term under the Licensed Patents, solely to make, have made (pursuant to Agreement), use, sell, offer for sale and import the Licensed Products in the Territory in and for the Field. (No license, exclusive or nonexclusive, is granted hereunder under the Licensed Patents, except to so make, have made, use, sell, offer for sale and import the Licensed Products in the Territory in and for the Field.)
License Property
Patents
5,874,418 – Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
6,046,177 – Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
6,133,248 – Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof

Licensed Product means (a) a Compound combined with or formulated using Captisol for ultimate use in humans in a dosage form/formulation, or (b) a pharmaceutical composition that includes a Compound and that is developed with the assistance of or incorporates any then-confidential component of the Captisol Data Package.

Compound means the proprietary Licensee isoflavone-based drug compound known as ME-143 (also known as NV-143) or the proprietary Licensee mitochondrial inhibitor drug compound known as ME-344, or any derivative, homolog, or analog of ME-143 or ME-344 or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing.

Captisol Related Compound means Captisol or any derivative, homolog analog of Captisol or any isomer, salt, hydrate, solvate, amide, ester, metabolite or product of any of the foregoing, including without limitation sulfobutylether g(gamma) cyclodextrin sodium salt.

Licensed Product Family means one or more Licensed Products which are based on the same Compound(s) (or any isomers, salts, hydrates, solvates, amides, esters, metabolites, or prodrugs of the foregoing), irrespective of whether such Licensed Products contain different dosage forms, proportions or formulations of such Compound(s), utilize different inactive ingredients and/or are marketed for different indications. Notwithstanding the foregoing, a Licensed Product based on a Compound shall be deemed to be in a distinct Licensed Product Family from a Licensed Product based on the combination of the same relevant Compound with any other active pharmaceutical ingredient. As such, if Licensee develops one Licensed Product with ME-344 as the sole active ingredient with Captisol and also develops another Licensed Product with ME-344 in combination with another active ingredient with Captisol, then two distinct sets of milestone payments shall be potentially due under this Agreement, one for each of such two distinct Licensed Products.

Field of Use
Captisol® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).

Captisol is  for use with the Licensee’s isoflavone-based drug compounds.

ME-344 is our isoflavone-derived mitochondrial inhibitor drug candidate. In preclinical studies, ME-344 has been shown to cause cell death in multiple human tumor cell lines, including ovarian cancer stem cells, by interfering with mitochondrial energy generation.

Field means the entire field of prevention, diagnosis and treatment of all human and animal diseases and disorders with the exceptions of (i) ocular treatment of any disease or condition with a formulation including a hormone; (ii) topical ocular treatment of inflammatory conditions; (iii) treatment and prophylaxis of fungal infections in humans; and (iv) any ocular treatment for retinal degeneration.

IPSCIO Record ID: 280841

License Grant
Licensor hereby grants to Licensee, an exclusive license under the Licensor Patents and Technical Information, and Licensors interest in Joint Patent Rights, to market, promote, use, distribute, sell, have sold and to import and export Product for the OTC Field within the Territory, provided that Licensor grants only a non-exclusive license under U.S. Patent No. 5,225,197 and corresponding patents throughout the world. In addition to the  foregoing, Licensee shall have an exclusive license under the Licensor Patents and Technical Information, and Licensors interest in the Joint Patent Rights, to make (and to have made) Product for the OTC Field in the Territory and the applicable provisions of the Supply Agreement.
License Property
Product means rapid dissolving tablets containing 10 milligrams Active Ingredient meeting the Specifications. The Product shall be pharmaceutically equivalent and bioequivalent to Claritin(R) Reditabs containing 10 milligrams Active Ingredient.

Licensor Patents shall mean those Patents and Patent applications owned or Controlled by Licensor during the Term of this Agreement that claim the Product, its manufacture or method of use, the DuraSolv(TM) technology or the OraSolv(R) technology, including the Patents and Patent applications which are set forth hereto.

5,225,197 – Pharmaceutical formulation
5,178,878 – Effervescent dosage form with microparticles
6,024,981 – Rapidly dissolving robust dosage form

Active Ingredient means ethyl 4-(8-chloro-5, 6-dihydro-11H-benzo [5,6] cyclohepta [1,2-b] pyridin-11-ylid-ene)-1 piperidinecarboxylate, known as loratadine.

Field of Use
OTC Field means the area of non-prescription (i.e., not requiring, by law or regulation, a prescription from a medical doctor) and/or over-the-counter sales for all human pharmaceutical uses.

Licensee will use the technology for a planned over-the-counter generic version of Claritin.
Claritin (loratadine) is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose. Claritin is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching, and other cold or allergy symptoms.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.